Pseudoxanthoma Elasticum Clinical Presentation
- Author: L Frank Glass, MD; Chief Editor: Dirk M Elston, MD more...
History
Cutaneous changes are usually the first manifestation of pseudoxanthoma elasticum (PXE), classically arising on the lateral aspect of the neck. They are generally asymptomatic but may be of cosmetic concern.
Extracutaneous presentations include mucosal involvement leading to gastrointestinal hemorrhage with melena, frank bleeding, occult blood in the stool, or hematemesis.
Patients may report fatigue from chronic blood loss or claudication from blood vessel involvement.
Slowly, as the disease progresses, patients note more severe cutaneous and cardiovascular manifestations, such as angina and hypertension.
Hematuria has also been reported.
Retinal hemorrhages with loss of central vision are common after the fourth decade of life.
Physical
Physical findings of pseudoxanthoma elasticum can be divided into cutaneous, ocular, and cardiovascular manifestations.
Cutaneous manifestations
The cutaneous manifestations of pseudoxanthoma elasticum are highly characteristic. The lesions usually develop in childhood or early adolescence; however, occasionally, they first appear in late adulthood.[9, 11, 12]
Small, yellow papules of 1-5 mm in diameter are seen in a linear or reticular pattern and may coalesce to form plaques.[13] The skin takes on a plucked chicken, Moroccan leather, or cobblestone appearance. Typically, these changes are first noted on the lateral part of the neck and later involve the antecubital fossae; the axillae; the popliteal spaces; the inguinal and periumbilical areas; the oral mucosa involving the lower lip, cheek, and palate; and the vaginal and rectal mucosae.[14]
As the disease progresses, the skin of the neck, the axillae, and the groin may become soft, lax, and wrinkled, hanging in folds. The extent of these changes is usually limited, but generalized cutis laxa–like pseudoxanthoma elasticum has also been reported.[15]
Horizontal and oblique mental creases before age 30 years is highly specific for pseudoxanthoma elasticum.[16]
Other clinical presentations reported in literature include acneiform lesions, brown reticulated macules and chronic granulomatous nodules.[17, 16]
Elastosis perforans serpiginosa may coexist with pseudoxanthoma elasticum.
The cutaneous lesions of pseudoxanthoma elasticum usually remain unchanged throughout life, and are generally symmetrically distributed. See the images below.
Classic cobblestone appearance with yellow papules and plaques on the lateral aspect of the neck.
Laxity and redundant skin folds in the axilla.
Flesh-colored reticulated plaques on the posterior neck. Ocular manifestations
The characteristic ocular manifestations of pseudoxanthoma elasticum are angioid streaks of the retina, which are slate gray to reddish brown curvilinear bands that radiate from the optic disc.[18] The streaks represent cracks and fissures in the calcified Bruch’s membrane. This ocular change is generally bilateral and is often noted several years after the onset of cutaneous lesions. Angioid streaks are present in 85% of patients with pseudoxanthoma elasticum.
Although these lesions are highly characteristic of pseudoxanthoma elasticum, they are not pathognomonic because they are also found in various other conditions including sickle cell anemia, thalassemia, Paget disease of the bone, Marfan syndrome, Ehlers-Danlos syndrome, and lead poisoning.
Angioid streaks are often preceded by peau d’orange changes, consisting of fine-yellow drusenlike pigment irregularities. These changes arise on average 1-8 years prior to angioid streaks, and suggest early retinopathy.[19]
Angioid streaks can serve as a nidus for choroidal neovascularization, which is associated with retinal hemorrhage and a poor prognosis if left untreated. Loss of central vision is progressive with each hemorrhage, but peripheral vision is spared.
Chorioretinal atrophies with a “comet tail” appearance appear to be pathognomonic for pseudoxanthoma elasticum, but their expression widely varies.[20]
Cardiovascular manifestations
Cardiovascular manifestations, except for intermittent claudication, are usually the last complications to be recognized in pseudoxanthoma elasticum. Calcification of the elastica media and intima of the blood vessels leads to various physical findings. In adults, peripheral pulses are often severely diminished. Renal artery involvement is rare, but can lead to hypertension, and coronary artery disease can result in angina pectoris and subsequent myocardial infarction.[8] Mitral valve prolapse has a higher prevalence in pseudoxanthoma elasticum. This prolapse may not be significant unless the murmur of mitral valve insufficiency is also present.[18]
GI hemorrhage, usually gastric in origin, results from the increased fragility of calcified submucosal vessels.[4] Hemorrhaging may occur early in the disease progression, especially in the second to fourth decade, without warning. Depending on its severity, hospitalization, blood transfusion, and surgery may be necessary. Approximately 10-15% of patients with pseudoxanthoma elasticum experience a GI hemorrhage at some point in their lives. Less commonly, hemorrhaging may occur in the urinary tract or cerebrovascular system. Hematuria or potentially fatal increases in intracranial pressure can be found in these cases, respectively.[13, 21]
Diagnostic criteria
A revised set of criteria has recently been proposed to aid in the diagnosis of pseudoxanthoma elasticum.[22] In order to make a definitive diagnosis, major criteria from two separate categories must be met; for a probable diagnosis, two major criteria from within the same category (skin or eye) or one major criterion and one or more minor criterion from another category must be present. A possible diagnosis is made when only one major criterion or only minor criteria are found.
Major diagnostic criteria include the following:
- Skin - Yellow papules/plaques on the lateral neck or body, skin biopsy showing increased calcification with clumping of elastic fiber taken from affected skin
- Eye - Peau d’orange changes, angioid streaks (confirmed by angiography)
- Genetics - Presence of a pathogenic mutation of both alleles of ABCC6, a first-degree relative who meets criteria for definitive pseudoxanthoma elasticum.
Minor diagnostic criteria include the following:
- Eye - One angioid streak shorter than one disk diameter, “comets” in the retina, one or more “wing signs” on the retina
- Genetics - A pathogenic mutation in one allele of the ABCC6 gene
Causes
Pseudoxanthoma elasticum is caused by mutations in the ABCC6,[10, 23] also known as multidrug resistance–associated protein 6 (MRP6), which has been mapped to 16p13.1. To date, greater than 150 different disease-causing mutations, mainly missense and nonsense mutations, have been identified in the 31 exons coding ABCC6. Because the ABCC6 gene encodes the cellular transport protein ABCC6/MRP6, pseudoxanthoma elasticum may represent a systemic metabolic disorder rather than a purely structural disorder of connective tissue.
In support of this hypothesis, fibroblasts grown in the sera of patients with pseudoxanthoma elasticum interfered with the normal assembly of elastic fibers in vitro.[23] Most recent studies support the notion that pseudoxanthoma elasticum is primarily a systemic metabolic disorder with secondary mineralization of connective tissues.[24]
The pathological changes found in pseudoxanthoma elasticum may be due to increased oxidative stress, resulting in elevated levels of intercellular adhesion molecule-1 (ICAM-1) and P-selectin.[25, 26, 27] One hypothesis is that ABCC6 secretes a vitamin-K precursor from the liver, supported by the finding that clinical features simulating pseudoxanthoma elasticum are seen in rats treated with vitamin-K antagonists and in patients with mutations of gamma-glutamyl carboxylase gene. Based on this theory, a precursor of vitamin-K that can be used by peripheral tissues should abate the process of pseudoxanthoma elasticum.[26] However, this has not been observed, and furthermore, supplementation with antioxidants such as vitamins C and E, selenium, and N -acetylcysteine have not been found to modify the ectopic mineralization process.[28]
Neldner KH. Pseudoxanthoma elasticum. Int J Dermatol. Mar 1988;27(2):98-100. [Medline].
Connor PJ Jr, Juergens JL, Perry HO, Hollenhorst RW, Edwards JE. Pseudoxanthoma elasticum and angioid streaks. A review of 106 cases. Am J Med. Apr 1961;30:537-43. [Medline].
Pope FM. Historical evidence for the genetic heterogeneity of pseudoxanthoma elasticum. Br J Dermatol. May 1975;92(5):493-509. [Medline].
Goodman RM, Smith EW, Paton D, Bergman RA, Siegel CL, Ottesen OE, et al. Pseudoxanthoma elasticum: A clinical and histopathological study. Medicine (Baltimore). Sep 1963;42:297-334. [Medline].
Eddy D. Pseudoxanthoma elasticum. Internal manifestations. A report of cases and a statistical review of the literature. Arch Dermatol. 1962;86:729-40.
Rigal D. Observation pour server a l'histoire de la cheloide diffuse xanthelmique. Annales de dermatologie et de syphiligraphie. 1881;2:491-5.
Darier J. Pseudoxanthoma elasticum. Monatshefte Praktische. 1896;23:609-17.
Hacker SM, Ramos-Caro FA, Beers BB, Flowers FP. Juvenile pseudoxanthoma elasticum: recognition and management. Pediatr Dermatol. Mar 1993;10(1):19-25. [Medline].
Bercovitch L, Terry P. Pseudoxanthoma elasticum 2004. J Am Acad Dermatol. Jul 2004;51(1 Suppl):S13-4. [Medline].
Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet. Dec 2005;42(12):881-92. [Medline].
Sherer DW, Bercovitch L, Lebwohl M. Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. J Am Acad Dermatol. Mar 2001;44(3):534-7. [Medline].
Li TH, Tseng CR, Hsiao GH, Chiu HC. An unusual cutaneous manifestation of pseudoxanthoma elasticum mimicking reticulate pigmentary disorders. Br J Dermatol. Jun 1996;134(6):1157-9. [Medline].
McDonald HR, Schatz H, Aaberg TM. Reticular-like pigmentary patterns in pseudoxanthoma elasticum. Ophthalmology. Mar 1988;95(3):306-11. [Medline].
Spinzi G, Strocchi E, Imperiali G, Sangiovanni A, Terruzzi V, Minoli G. Pseudoxanthoma elasticum: a rare cause of gastrointestinal bleeding. Am J Gastroenterol. Aug 1996;91(8):1631-4. [Medline].
Uenishi T, Uchiyama M, Sugiura H, Danno K. Pseudoxanthoma elasticum with generalized cutaneous laxity. Arch Dermatol. May 1997;133(5):664-6. [Medline].
Lebwohl M, Lebwohl E, Bercovitch L. Prominent mental (chin) crease: a new sign of pseudoxanthoma elasticum. J Am Acad Dermatol. Apr 2003;48(4):620-2. [Medline].
Li TH, Tseng CR, Hsiao GH, Chiu HC. An unusual cutaneous manifestation of pseudoxanthoma elasticum mimicking reticulate pigmentary disorders. Br J Dermatol. Jun 1996;134(6):1157-9. [Medline].
Lebwohl MG, Distefano D, Prioleau PG, Uram M, Yannuzzi LA, Fleischmajer R. Pseudoxanthoma elasticum and mitral-valve prolapse. N Engl J Med. Jul 22 1982;307(4):228-31. [Medline].
Finger RP, Charbel Issa P, Ladewig MS, et al. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol. Mar-Apr 2009;54(2):272-85. [Medline].
Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol. Jul-Aug 2003;48(4):424-38. [Medline].
Heaton JP, Wilson JW. Pseudoxanthoma elasticum and its urological implications. J Urol. Apr 1986;135(4):776-7. [Medline].
Plomp AS, Toonstra J, Bergen AA, van Dijk MR, de Jong PT. Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A. Apr 2010;152A(4):1049-58. [Medline].
Katona E, Aslanidis C, Remenyik E, Csikós M, Kárpáti S, Paragh G, et al. Identification of a novel deletion in the ABCC6 gene leading to Pseudoxanthoma elasticum. J Dermatol Sci. Nov 2005;40(2):115-21. [Medline].
Ringpfeil F, Pulkkinen L, Uitto J. Molecular genetics of pseudoxanthoma elasticum. Exp Dermatol. Aug 2001;10(4):221-8. [Medline].
Li Q, Jiang Q, Uitto J. Pseudoxanthoma elasticum: oxidative stress and antioxidant diet in a mouse model (Abcc6-/-). J Invest Dermatol. May 2008;128(5):1160-4. [Medline].
Hendig D, Adam A, Zarbock R, Szliska C, Kleesiek K, Götting C. Elevated serum levels of intercellular adhesion molecule ICAM-1 in Pseudoxanthoma elasticum. Clin Chim Acta. Aug 2008;394(1-2):54-8. [Medline].
Götting C, Adam A, Szliska C, Kleesiek K. Circulating P-, L- and E-selectins in pseudoxanthoma elasticum patients. Clin Biochem. Apr 2008;41(6):368-74. [Medline].
Le Saux O, Bunda S, VanWart CM, Douet V, Got L, Martin L, et al. Serum factors from pseudoxanthoma elasticum patients alter elastic fiber formation in vitro. J Invest Dermatol. Jul 2006;126(7):1497-505. [Medline].
Ratajewski M, Bartosz G, Pulaski L. Expression of the human ABCC6 gene is induced by retinoids through the retinoid X receptor. Biochem Biophys Res Commun. Dec 1 2006;350(4):1082-7. [Medline].
Viljoen DL, Bloch C, Beighton P. Plastic surgery in pseudoxanthoma elasticum: experience in nine patients. Plast Reconstr Surg. Feb 1990;85(2):233-8. [Medline].
Galadari H, Lebwohl M. Pseudoxanthoma elasticum: Temporary treatment of chin folds and lines with injectable collagen. J Am Acad Dermatol. Nov 2003;49(5 Suppl):S265-6. [Medline].
Bhatnagar P, Freund KB, Spaide RF, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina. Sep 2007;27(7):897-902. [Medline].
Myung JS, Bhatnagar P, Spaide RF, Klancnik JM Jr, Cooney MJ, Yannuzzi LA. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina. May 2010;30(5):748-55. [Medline].
Yoo JY, Blum RR, Singer GK, et al. A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol. Apr 13 2011;[Medline].
Arndt KA, LeBoit PE. Inherited elastic tissue malformation. In: Cutaneous Medicine and Surgery. Vol 1. Philadelphia, Pa: WB Saunders; 1996:1770-74.
Bercovitch L, Terry P. Pseudoxanthoma elasticum 2004. J Am Acad Dermatol. Jul 2004;51(1 Suppl):S13-4. [Medline].
Borst P, van de Wetering K, Schlingemann R. Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery?. Cell Cycle. Jun 1 2008;7(11):1575-9. [Medline].
Champion RH, Burton JL. Disorders of Connective Tissue. In: Champion H, Burton JL, Burns DA, Breathnach SM, eds. Rook/Wilkinson/Ebling Textbook of Dermatology. Vol 6. Boston, Mass: Blackwell Science; 1998:2022-6.
Freedberg IM, Eisen AZ. Heritable disorders of connective tissue with skin changes. In: Fitzpatrick's Dermatology In General Medicine. Vol 5. New York, NY: McGraw-Hill; 1999:1843-44.
Hurwitz S. Hereditary skin disorders: the genodermatoses. In: Clinical Pediatric Dermatology. Vol 2. Philadelphia, Pa: WB Saunders; 1993:183-4.
Jiang Q, Endo M, Dibra F, Wang K, Uitto J. Pseudoxanthoma Elasticum Is a Metabolic Disease. J Invest Dermatol. Aug 7 2008;[Medline].
Laube S, Moss C. Pseudoxanthoma elasticum. Arch Dis Child. Jul 2005;90(7):754-6. [Medline].
Lebwohl M, Phelps RG, Yannuzzi L, Chang S, Schwartz I, Fuchs W. Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. N Engl J Med. Aug 6 1987;317(6):347-50. [Medline].
Tsuji T. Three-dimensional architecture of altered dermal elastic fibers in pseudoxanthoma elasticum: scanning electron microscopic studies. J Invest Dermatol. May 1984;82(5):518-21. [Medline].

